A newly published study on the use of guanfacine extended release (GXR) in individuals with Prader-Willi syndrome (PWS) marks an important step forward in addressing challenging behaviors such as aggression, skin-picking, and hyperactivity. Funded by FPWR, this was the first randomized,...
Source: FPWR Blog
|
Published: July 7 2025 - 09:00 AM
We’re excited to share that Acadia Pharmaceuticals has officially completed enrollment for its Phase 3 COMPASS PWS clinical trial of ACP-101 in individuals with Prader-Willi syndrome (PWS)—three months ahead of schedule!
Source: FPWR Blog
|
Published: July 7 2025 - 06:15 AM
FPWR maintains the latest clinical trial information so that you can stay abreast of trial opportunities. Some trials require in-person visits, while others can be completed remotely. Some trials are testing new drugs, while others are intervention (non-drug) or natural history studies. Details of...
Source: FPWR Blog
|
Published: July 7 2025 - 12:34 PM
Did you know that swallowing issues are extremely common in babies with Prader-Willi syndrome (PWS)? A recent study from Cook Children’s Medical Center (CCMC) in Texas took a closer look—and what they found is something every clinician and parent of a child with PWS should know.
Source: FPWR Blog
|
Published: July 7 2025 - 11:00 AM
Thanks to nearly 2,000 participants completing a collective 61,795 surveys, the Global PWS Registry continues to be a vital resource for the PWS community—adding to our body of knowledge, improving how we care for our loved ones, and helping inform and accelerate clinical trials.
Source: FPWR Blog
|
Published: June 6 2025 - 09:00 AM
